Asset profile
vedolizumab · Entyvio
Monoclonal antibody
Evidence outlook
Approved: Crohn's Disease, Ulcerative Colitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
86 competitors in this universe: 2 direct rivals (same mechanism and indication), 1 same-class, 83 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Vedolizumab (Entyvio): this drug | Approved | Monoclonal antibody | α4β7 integrin | ||
| Morf-057 | Phase 2 | Small molecule | α4β7 integrin | ||
| SPY001 | Phase 2 | Monoclonal antibody | α4β7 integrin | ||
| Trosunilimab | Phase 2 | Monoclonal antibody | α4β7 integrin | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Aacf (Idacio) | Approved | — | TNF-alpha | ||
| Adalimumab-Aaty (Yuflyma) | Approved | — | TNF-alpha | ||
| Adalimumab-Adaz (Hyrimoz) | Approved | — | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Afzb (Abrilada) | Approved | — | TNF-alpha | ||
| Adalimumab-Aqvh (Yusimry) | Approved | — | TNF-alpha | ||
| Adalimumab-Atto (Amjevita) | Approved | — | TNF-alpha | ||
| Adalimumab-Bwwd (Hadlima) | Approved | — | TNF-alpha | ||
| Adalimumab-Fkjp (Hulio) | Approved | — | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Balsalazide Disodium (Colazal) | Approved | — | Aminosalicylate |
…and 71 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(25 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
2027 (13)
May 2027 (1)
What to watch
June 2027 (3)
What to watch
What to watch
What to watch
July 2027 (2)
August 2027 (2)
September 2027 (2)
October 2027 (1)
What to watch
December 2027 (2)
What to watch
What to watch
2028 (4)
April 2028 (1)
What to watch
May 2028 (1)
What to watch
October 2028 (2)
What to watch
What to watch
2029 (1)
January 2029 (1)
What to watch
2030 (5)
January 2030 (1)
March 2030 (1)
What to watch
June 2030 (1)
What to watch
August 2030 (1)
What to watch
December 2030 (1)
What to watch
2033 (1)
February 2033 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.